1094-Cardiac Fibrosis Clearance and Myocardial Regeneration

Paper Talk · Jun 7, 2026 · 26m

This research introduces pleiotropic chimeric antigen receptor-monocytes (pCAR-Mos) as a dual-action cell therapy designed to treat heart failure following a myocardial infarction. By engineering monocytes to target fibroblast activation protein (FAP) and secrete the regenerative protein Agrin, the study demonstrates a synergistic approach that clears pathogenic fibrosis while simultaneously promoting cardiomyocyte proliferation and angiogenesis. Unlike traditional CAR-T or CAR-macrophage treatments, these engineered monocytes show superior cardiac homing capabilities and a more favorable…